Hectic M&A activity as an alternative to internal R&D investments in drugs and a boon for shareholders.
Competition from generic and biosimilar drugs eating away at patented drugs' market shares. Rise in new drug launches in the U.S. market along with mounting criticism over drug pricing issues by the
Democrats in the United States Congress.
Pharmaceuticals: Worldwide prescription drug sales expected to rise by +3% in 2016 - Report
Competition from generic and biosimilar drugs eating away at patented drugs' market shares. Rise in new drug launches in the U.S. market along with mounting criticism over drug pricing issues by the
Democrats in the United States Congress.
Pharmaceuticals: Worldwide prescription drug sales expected to rise by +3% in 2016 - Report